Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia



Status:Recruiting
Conditions:Cancer, Other Indications, Blood Cancer
Therapuetic Areas:Oncology, Other
Healthy:No
Age Range:Any - 21
Updated:3/31/2019
Start Date:October 6, 2017
End Date:December 30, 2020

Use our guide to learn which trials are right for you!

A Phase 2 Study of the MEK Inhibitor Trametinib (NSC# 763093) in Children With Relapsed or Refractory Juvenile Myelomonocytic Leukemia

This phase II trial studies how well trametinib works in treating patients with juvenile
myelomonocytic leukemia that has come back or does not respond to treatment. Trametinib may
stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

PRIMARY OBJECTIVES:

I. To determine the objective response rate to trametinib in children with recurrent or
refractory juvenile myelomonocytic leukemia (JMML).

SECONDARY OBJECTIVES:

I. To further define and describe the toxicities of single agent trametinib in children with
recurrent or refractory JMML.

II. To further characterize the pharmacokinetics of trametinib in children with recurrent or
refractory JMML.

III. To prospectively evaluate mutant allele burden as a marker of disease activity in JMML.

IV. To measure the objective response rate to 12 cycles of trametinib in children with
recurrent or refractory JMML.

V. To measure the rate of complete responses in children with recurrent or refractory JMML.

VI. To measure the duration of response among responders.

TERTIARY OBJECTIVES:

I. To describe the distribution of JMML diagnostic criteria in children with recurrent or
refractory JMML.

OUTLINE:

Patients receive trametinib orally (PO) once daily (QD) on days 1-28. Treatment repeats every
28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up annually for up to 5 years.

Inclusion Criteria:

- Patients must have had histologic verification of juvenile myelomonocytic leukemia
(JMML) at original diagnosis and currently have relapsed or refractory disease; the
diagnosis is made based on the following criteria

- JMML category 1 (all of the following): the diagnostic criteria must include all
features in category 1 and EITHER (i) one of the features in category 2 OR (ii)
two features from category 3 to make the diagnosis

- Splenomegaly

- > 1000 (1 x 10^9/uL) circulating monocytes

- < 20% blasts in the bone marrow or peripheral blood

- Absence of the t(9;22) or BCR/ABL fusion gene

- JMML category 2 (at least one of the following if at least two category 3
criteria are not present):

- Somatic mutation in RAS or PTPN11

- Clinical diagnosis of NF1 or NF1 gene mutation

- Homozygous mutation in CBL

- Monosomy 7

- JMML category 3 (at least two of the following if no category 2 criteria are
met):

- Circulating myeloid precursors

- White blood cell count, > 10 000 (10 x 10^9/ uL)

- Increased hemoglobin F for age

- Clonal cytogenetic abnormality

- GM-CSF hypersensitivity

- Patients with refractory or relapsed JMML must have had at least one cycle of
intensive frontline therapy or at least 2 cycles of a deoxyribonucleic acid (DNA)
demethylating agent with persistence of disease, defined by clinical symptoms or the
presence of a clonal abnormality; frontline therapy is defined as one cycle of
intravenous chemotherapy that includes of any of the following agents: fludarabine,
cytarabine, or any anthracycline but specifically excludes oral 6-mercaptopurine;
frontline therapy will also include any conditioning regimen as part of a stem cell
transplant; patients who transform to AML at any point with more than 20% blasts are
not eligible for this trial

- Patients must have a Lansky or Karnofsky performance status score of >= 50,
corresponding to Eastern Cooperative Oncology Group (ECOG) categories 0, 1 or 2; use
Karnofsky for patients > 16 years of age and Lansky for patients =< 16 years of age;
patients who are unable to walk because of paralysis, but who are up in a wheelchair,
will be considered ambulatory for the purpose of assessing the performance score

- Patients must have fully recovered from the acute toxic effects of all prior
chemotherapy, immunotherapy, or radiotherapy prior to study enrollment

- Myelosuppressive chemotherapy: patients must have completely recovered from all
acute toxic effects of chemotherapy, immunotherapy or radiotherapy prior to study
enrollment; at least 14 days must have elapsed since the completion of cytotoxic
therapy, with the exception of hydroxyurea

- Note: cytoreduction with hydroxyurea can be initiated and continued for up
to 24 hours prior to the start of protocol therapy

- Hematopoietic growth factors: at least 14 days after the last dose of a
long-acting growth factor (e.g., pegfilgrastim) or 7 days for short-acting growth
factor; for agents that have known adverse events occurring beyond 7 days after
administration, this period must be extended beyond the time during which adverse
events are known to occur

- Biologic (anti-neoplastic agent): at least 7 days must have elapsed since
completion of therapy with a biologic agent; for agents that have known adverse
events occurring beyond 7 days after administration, this period prior to
enrollment must be extended beyond the time during which adverse events are known
to occur

- Monoclonal antibodies:

- At least 30 days after the completion of any type of immunotherapy, e.g.
tumor vaccines

- At least 3 half-lives must have elapsed since prior therapy that included a
monoclonal antibody

- Radiotherapy:

- >= 2 weeks must have elapsed since local palliative external radiation
therapy (XRT) (small port)

- >= 6 months must have elapsed if prior craniospinal XRT was received, if >=
50% of the pelvis was irradiated, or if traumatic brain injury (TBI) was
received

- >= 4 weeks must have elapsed if other substantial bone marrow irradiation
was given

- Stem cell transplant or rescue without TBI: no evidence of active graft versus
(vs.) host disease and >= 3 months must have elapsed since transplant

- Patients must not be known to be refractory to red blood cell or platelet transfusions

- Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70
mL/min/1.73 m^2 or a serum creatinine based on age/gender as follows:

- Age: Maximum serum creatinine (mg/dL)

- 1 month to < 6 months: 0.4 (male) 0.4 (female)

- 6 months to < 1 year: 0.5 (male) 0.5 (female)

- 1 to < 2 years: 0.6 (male) 0.6 (female)

- 2 to < 6 years: 0.8 (male) 0.8 (female)

- 6 to < 10 years: 1 (male) 1 (female)

- 10 to < 13 years: 1.2 (male) 1.2 (female)

- 13 to < 16 years: 1.5 (male) 1.4 (female)

- >= 16 years: 1.7 (male) 1.4 (female)

- Total bilirubin =< 1.5 x upper limit of normal (ULN) for age

- Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =< 3 x
ULN (=< 135 U/L) (for the purpose of this study, the ULN for SGPT is 45 U/L)

- Serum albumin >= 2 g/dL

- Shortening fraction of >= 27% by echocardiogram OR ejection fraction of >= 50% by
multi-gated acquisition (MUGA)

- Corrected QT (by Bazett's formula [QTcB]) interval < 450 msecs

- Patients must be able to swallow tablets or liquid; use of a nasogastric or
gastrostomy (G) tube is also allowed

Exclusion Criteria:

- Patients who are pregnant or breast-feeding are not eligible for this study as there
is yet no available information regarding human fetal or teratogenic toxicities;
negative pregnancy tests must be obtained in girls who are post-menarchal; patients of
reproductive potential may not participate unless they have agreed to use an effective
contraceptive method for the duration of study therapy; women of childbearing
potential should be advised to use effective contraception for 4 months after the last
dose of trametinib; breastfeeding women are excluded; female patients should not
breastfeed during treatment with trametinib, and for 4 months following the last dose;
male patients must use a condom during intercourse and agree not to father a child
during therapy and for 4 months following discontinuation of trametinib to avoid
unnecessary exposure of trametinib to the fetus

- Concomitant Medications

- Corticosteroids: patients requiring corticosteroids who have not been on a stable
or decreasing dose of corticosteroid for the 7 days prior to enrollment are not
eligible; if used to modify immune adverse events related to prior therapy, >= 14
days must have elapsed since last dose of corticosteroid

- Note: hydrocortisone used as a pre-medication to prevent transfusion related
reactions is not considered a concomitant corticosteroid

- Investigational drugs: patients who are currently receiving another
investigational drug are not eligible

- Anti-cancer agents: patients who are currently receiving other anti-cancer agents
are not eligible (except patients receiving hydroxyurea, which may be continued
until 24 hours prior to start of protocol therapy)

- Anti-graft versus host disease (GVHD) or agents to prevent organ rejection
post-transplant: patients who are receiving cyclosporine, tacrolimus or other
agents to prevent either graft-versus-host disease post bone marrow transplant or
organ rejection post-transplant are not eligible for this trial

- Cardiac medications: any medications for treatment of left ventricular systolic
dysfunction

- Patients who have an uncontrolled infection are not eligible

- Patients who in the opinion of the investigator may not be able to comply with the
safety monitoring requirements of the study are not eligible

- Patients with a history of hepatic sinusoid obstructive syndrome (veno-occlusive
disease) within the prior 3 months

- Patients with a history of current evidence/risk of retinal vein occlusion (RVO) or
central serous retinopathy (CSR)

- Patients with a history of RVO or CSR, or predisposing factors to RVO or CSR (e.g.,
uncontrolled glaucoma or ocular hypertension)

- Uncontrolled systemic disease(s) such as hypertension or diabetes mellitus; blood
pressure must be =< the 95th percentile for age, height, and gender

- History of allergic reaction attributed to compounds of similar chemical or biologic
composition to the MEK inhibitor, trametinib

- Patients who are able to swallow capsules or liquid or able to use a nasogastric or G
tube are eligible
We found this trial at
43
sites
San Francisco, California 94158
Principal Investigator: Elliot Stieglitz
Phone: 877-827-3222
?
mi
from
San Francisco, CA
Click here to add this to my saved trials
1600 7th Avenue
Birmingham, Alabama 35233
(205) 638-9100
Principal Investigator: Matthew A. Kutny
Children's Hospital of Alabama Children
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
3333 Burnet Avenue # Mlc3008
Cincinnati, Ohio 45229
 1-513-636-4200 
Principal Investigator: James I. Geller
Cincinnati Children's Hospital Medical Center Patients and families from across the region and around the...
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
700 Childrens Drive
Columbus, Ohio 43205
(616) 722-2000
Principal Investigator: Mark A. Ranalli
Nationwide Children's Hospital At Nationwide Children’s, we are creating the future of pediatric health care....
?
mi
from
Columbus, OH
Click here to add this to my saved trials
282 Washington St
Hartford, Connecticut 06106
(860) 545-9000
Principal Investigator: Michael S. Isakoff
Connecticut Children's Medical Center Connecticut Children’s Medical Center is a nationally recognized, 187-bed not-for-profit children’s...
?
mi
from
Hartford, CT
Click here to add this to my saved trials
262 Danny Thomas Pl
Memphis, Tennessee 38105
(901) 495-3300
Principal Investigator: Jeffrey E. Rubnitz
St. Jude Children's Research Hospital St. Jude is unlike any other pediatric treatment and research...
?
mi
from
Memphis, TN
Click here to add this to my saved trials
1201 W La Veta Ave
Orange, California 92868
(714) 997-3000
Principal Investigator: Elyssa M. Rubin
Children's Hospital of Orange County For more than 45 years, CHOC Children’s has been steadfastly...
?
mi
from
Orange, CA
Click here to add this to my saved trials
South 34th Street
Philadelphia, Pennsylvania 19104
 215-590-1000
Principal Investigator: Elizabeth Fox
Phone: 800-411-1222
Children's Hospital of Philadelphia Since its start in 1855 as the nation's first hospital devoted...
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
4401 Penn Avenue
Pittsburgh, Pennsylvania 15224
412-692-5325
Principal Investigator: Jean M. Tersak
Children's Hospital of Pittsburgh of UPMC UPMC is one of the leading nonprofit health systems...
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
3181 Southwest Sam Jackson Park Road
Portland, Oregon 97239
503 494-8311
Principal Investigator: Bill H. Chang
Phone: 503-494-1080
Oregon Health and Science University In 1887, the inaugural class of the University of Oregon...
?
mi
from
Portland, OR
Click here to add this to my saved trials
7700 Floyd Curl Dr
San Antonio, Texas 78229
(210) 575-7000
Principal Investigator: Vinod K. Gidvani-Diaz
Methodist Children's Hospital of South Texas Methodist Children
?
mi
from
San Antonio, TX
Click here to add this to my saved trials
1600 Rockland Road
Wilmington, Delaware 19803
(302) 651-4200
Principal Investigator: Scott M. Bradfield
Phone: 302-651-6884
Alfred I. duPont Hospital for Children Nemours began more than 70 years ago with the...
?
mi
from
Wilmington, DE
Click here to add this to my saved trials
1540 East Hospital Drive
Ann Arbor, Michigan 48109
(877) 475-6688
Principal Investigator: Rajen Mody
C S Mott Children's Hospital Behind the doors of C.S. Mott Children's Hospital there exist...
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Atlanta, Georgia 30322
Principal Investigator: Melinda G. Pauly
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
13123 E 16th Ave
Aurora, Colorado 80045
(720) 777-1234
Principal Investigator: Kelly W. Maloney
Children's Hospital Colorado At Children's Hospital Colorado, we see more, treat more and heal more...
?
mi
from
Aurora, CO
Click here to add this to my saved trials
450 Brookline Ave
Boston, Massachusetts 2215
617-632-3000
Principal Investigator: Yana Pikman
Phone: 877-442-3324
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
?
mi
from
Boston, MA
Click here to add this to my saved trials
Dallas, Texas 75390
Principal Investigator: Kathleen (Wiertel) Ludwig
Phone: 214-648-7097
?
mi
from
Dallas, TX
Click here to add this to my saved trials
Denver, Colorado 80218
Principal Investigator: Jennifer J. Clark
?
mi
from
Denver, CO
Click here to add this to my saved trials
9333 Imperial Highway
Downey, California 90242
Principal Investigator: Robert M. Cooper
Phone: 510-891-3400
?
mi
from
Downey, CA
Click here to add this to my saved trials
900 West Faris Rd.
Greenville, South Carolina 29605
(864)455-8898
Principal Investigator: Nichole L. Bryant
BI-LO Charities Children's Cancer Center The BI-LO Charities Children
?
mi
from
Greenville, SC
Click here to add this to my saved trials
Houston, Texas 77030
Principal Investigator: Rachel E. Rau
Phone: 713-798-1354
?
mi
from
Houston, TX
Click here to add this to my saved trials
705 Riley Hospital Dr
Indianapolis, Indiana 46202
(317) 944-5000
Principal Investigator: Kamnesh R. Pradhan
Phone: 800-248-1199
Riley Hospital for Children Riley Hospital for Children at IU Health is a place of...
?
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Iowa City, Iowa 52242
Principal Investigator: Mariko Sato
Phone: 800-237-1225
?
mi
from
Iowa City, IA
Click here to add this to my saved trials
Jacksonville, Florida 32207
Principal Investigator: Scott M. Bradfield
?
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Kansas City, Missouri 64108
Principal Investigator: Kevin F. Ginn
?
mi
from
Kansas City, MO
Click here to add this to my saved trials
Lexington, Kentucky
Principal Investigator: Vlad C. Radulescu
Phone: 859-257-3379
?
mi
from
Lexington, KY
Click here to add this to my saved trials
1 Children's Way
Little Rock, Arkansas 72202
(501) 364-1100
Principal Investigator: David L. Becton
Arkansas Children's Hospital Arkansas Children's Hospital (ACH) is the only pediatric medical center in Arkansas...
?
mi
from
Little Rock, AR
Click here to add this to my saved trials
11234 Anderson St
Loma Linda, California 92354
(909) 558-4000
Principal Investigator: Albert Kheradpour
Phone: 909-558-3375
Loma Linda University Medical Center An outgrowth of the original Sanitarium on the hill in...
?
mi
from
Loma Linda, CA
Click here to add this to my saved trials
Miami, Florida 33155
Principal Investigator: Enrique A. Escalon
?
mi
from
Miami, FL
Click here to add this to my saved trials
Miami, Florida 33136
Principal Investigator: Julio C. Barredo
Phone: 305-243-2647
?
mi
from
Miami, FL
Click here to add this to my saved trials
9000 W Wisconsin Ave #270
Milwaukee, Wisconsin 53226
(414) 266-2000
Principal Investigator: Michael J. Burke
Phone: 414-955-4727
Children's Hospital of Wisconsin Nothing matters more than our children. At Children's Hospital of Wisconsin,...
?
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Minneapolis, Minnesota 55455
Principal Investigator: Emily G. Greengard
?
mi
from
Minneapolis, MN
Click here to add this to my saved trials
2525 Chicago Ave
Minneapolis, Minnesota 55404
(612) 813-6000
Principal Investigator: Michael K. Richards
Children's Hospitals and Clinics of Minnesota - Minneapolis Children's Hospitals and Clinics of Minnesota is...
?
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Nashville, Tennessee 37203
Principal Investigator: Haydar A. Frangoul
?
mi
from
Nashville, TN
Click here to add this to my saved trials
New Hyde Park, New York 11040
Principal Investigator: Julie I. Krystal
?
mi
from
New Hyde Park, NY
Click here to add this to my saved trials
New York, New York 10029
Principal Investigator: Pillai Pallavi Madhusoodhan
Phone: 212-824-7309
?
mi
from
New York, NY
Click here to add this to my saved trials
940 NE 13th St
Oklahoma City, Oklahoma 73190
(405) 271-6458
Principal Investigator: Rene Y. McNall-Knapp
Phone: 405-271-8777
University of Oklahoma Health Sciences Center The OU Health Sciences Center is composed of seven...
?
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
13535 Nemours Parkway
Orlando, Florida 32827
(407) 567-4000
Principal Investigator: Scott M. Bradfield
Nemours Children's Hospital Nemours Children's Hospital in Orlando brings pediatric specialty care never before offered...
?
mi
from
Orlando, FL
Click here to add this to my saved trials
725 Welch Rd
Palo Alto, California 94304
(650) 497-8000
Principal Investigator: Sheri L. Spunt
Lucile Packard Children's Hospital Stanford University Stanford Children's Health is the only network in the...
?
mi
from
Palo Alto, CA
Click here to add this to my saved trials
1919 E Thomas Rd
Phoenix, Arizona 85006
(602) 933-1000
Principal Investigator: Jessica Boklan
Phone: 602-546-0920
Phoenix Children's Hospital Phoenix Children's Hospital has provided hope, healing, and the best healthcare for...
?
mi
from
Phoenix, AZ
Click here to add this to my saved trials
660 S Euclid Ave
Saint Louis, Missouri 63110
(314) 362-5000
Principal Investigator: Robert J. Hayashi
Phone: 800-600-3606
Washington University School of Medicine Washington University Physicians is the clinical practice of the School...
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
4800 Sand Point Way NE
Seattle, Washington 98105
(206) 987-2000
Principal Investigator: Julie R. Park
Seattle Children's Hospital Seattle Children’s Hospital specializes in meeting the unique physical, emotional and developmental...
?
mi
from
Seattle, WA
Click here to add this to my saved trials
Tampa, Florida 33607
Principal Investigator: Dana A. Obzut
?
mi
from
Tampa, FL
Click here to add this to my saved trials